The oral PCSK9 inhibitor enlicitide decanoate achieved 58% LDL-C reduction in patients with heterozygous familial hypercholesterolemia, offering a potential alternative to injectable therapies.
Researchers examine the strengths and shortcomings of the current European Alliance of Associations for Rheumatology definition for difficult-to-treat rheumatoid arthritis.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.
Metagenome analysis reveals strain-level functional differences and metabolic pathways that distinguish patients with coronary artery disease from healthy controls.